Summary of Conference Schedule

TUESDAY, 7 June 2005

08:00 a.m.  OPENING OF THE REGISTRATION DESK
01:00-05:00 p.m. WORKSHOP ON T-CELL LYMPHOMA (closed) (Room G)
               Chair: F.M. Foss (Boston USA), J.M. Vose (Nebraska, USA), E. Zucca (Bellinzona, Switzerland)
01:30-09:30 p.m. SATELLITE SYMPOSIA

WEDNESDAY, 8 June 2005

07:00 a.m.  POSTER SET UP I (Marquee Parco Ciani)
07:30 a.m.  POSTER SESSION I (Marquee Parco Ciani, authors present, posters posted the whole day)
09:00-09:45 a.m. MEET THE PROFESSOR (part I) (Rooms A, B1, B2, C, E, G)
               (repetition Thursday, 9 June, 07:30-08:15 a.m.)
               (parallel sessions)
10:00-10:45 a.m. MEET THE PROFESSOR (part II) (Rooms A, B1, B2, C, E, G)
               (repetition Friday, 10 June, 07:30-08:15 a.m.)
               (parallel sessions)
11:00-12:00 a.m. POSTER DISCUSSIONS WITH DISCUSSION LEADERS/ POSTER SESSION I
               (Rooms and sessions indicated in the Conference Schedule)
               (parallel sessions)
12:00-01:00 p.m. LUNCH AND OFFICIAL OPENING OF THE COMMERCIAL EXHIBITION
               (Marquee Parco Ciani)

01:00 p.m.  OPENING OF THE CONFERENCE (Room A/B)
01:10 p.m.  AWARD OF THE SAN SALVATORE FOUNDATION (Room A/B)
01:20 p.m.  HENRY KAPLAN MEMORIAL LECTURE (Room A/B)
02:10-03:45 p.m. SESSION 1 – VIROLOGY, EPIDEMIOLOGY (Room A/B)
04:00-05:45 p.m. SESSION 2 – MULTIPLE MYELOMA (Room A/B)
05:45-06:30 p.m. CONTROVERSY I – WHAT IS THE ROLE OF HIGH DOSE CHEMOTHERAPY FOR
                FOLLICULAR LYMPHOMA? (Room A/B)
07:00-09:00 p.m. SATELLITE SYMPOSIA

THURSDAY, 9 June 2005

07:30-08:15 a.m. MEET THE PROFESSOR (repetition part I, same speakers, same rooms)
08:30-09:45 a.m. SESSION 3 – IMMUNOTHERAPY (Room A)
08:30-09:40 a.m. SESSION 4 – BIOLOGY OF LYMPHOMAS I (Room B)
10:00-12:00 a.m. SESSION 5 – BIOLOGY OF LYMPHOMAS II (Room A/B)
12:00-12:45 p.m.  HENRY RAPPAPORT MEMORIAL LECTURE (Room A/B)
                KEY NOTE LECTURE I
01:00-02:00 p.m.  LUNCH, POSTVIEWING AND GUINNESS WORLD RECORD ATTEMPT
                (Marquee Parco Ciani)
02:00-03:20 p.m.  SESSION 6 – REVIEW LECTURES ON HODGKIN'S DISEASE (Room A/B)
03:00-03:20 p.m.  SPECIAL LECTURE (Room A/B)
                TREATMENT AND OUTCOME IN ADOLESCENTS AND YOUNG ADULTS WITH
                INTERMEDIATE AND AGGRESSIVE NON-HODGKIN'S LYMPHOMA
03:30-05:45 p.m.  SESSION 7 – CHRONIC LYMPHOCYTIC LEUKAEMIA (Room A/B)
05:45-06:30     CONTROVERSY II - IS R-CHOP THE STANDARD TREATMENT FOR DLCL? (Room A/B)
07:00-09:00 p.m.  SATELLITE SYMPOSIA

FRIDAY, 10 June 2005

07:00 a.m.       POSTER SET UP II (Marquee Parco Ciani)
07:30 a.m.       POSTER SESSION II (Marquee Parco Ciani, authors present, posters posted the whole day)
07:30-08:15 a.m. MEET THE PROFESSOR (repetition part II, same speakers, same rooms)
08:30-10:00 a.m. SESSION 8 – 10 YEARS WHO CLASSIFICATION (Room A/B)
10:15-11:50 a.m. SESSION 9 – MANTLE CELL LYMPHOMA (Room A/B)
12:00-12:45 p.m. JOHN ULTMANN MEMORIAL LECTURE (Room A/B)
                KEY NOTE LECTURE II
01:00-02:00 p.m. LUNCH WITH POSTVIEWING (Marquee Parco Ciani)
02:00-03:45 p.m. SESSION 10 – CLINICAL RESULTS IN LYMPHOMA I (Room A/B)
03:45-06:30 p.m. SESSION 11 – CLINICAL RESULTS IN LYMPHOMA II (Room A)
                (parallel session)
04:00-06:30 p.m. SESSION 12 – CLINICAL-PATHOLOGICAL CORRELATIONS (Room B)
                (parallel session)
04:00-06:30 p.m. SESSION 13 – PEDIATRIC LYMPHOMAS (Room C)
                (parallel sessions)
06:30-07:30 p.m. POSTER DISCUSSIONS WITH DISCUSSION LEADERS/ POSTER SESSION II
                (Rooms and sessions indicated in the Conference Schedule)
08:00 p.m.       LUGANO CIRCUS SCHOOL OF LYDIA GOLOYKOVA (Room A)
09:00-01:00 a.m. FAREWELL PARTY (Marquee Parco Ciani)
SATURDAY, 11 June 2005

08:30-11:00 a.m.  
(parallel sessions)

SESSION 14 – NEW AGENTS (Room A)

SESSION 15 – NEW TREATMENT MODALITIES (Room B)

SESSION 16 – NEW IMMUNOLOGICAL PRINCIPLES (Room C)

10:50

CLOSING REMARKS in Room A

11:00

CLOSE
Satellite Symposia Schedule

TUESDAY, 7 June 2005

01:30-3:30 p.m.  
parallel symposia  
Roche
**MABTHERA IN NHL/CLL: BRINGING SCIENCE TO LIFE** (Room A)  
Chair: D.G. Maloney (Seattle, USA)

Zeneus Pharma Ltd.
**ADVANCES IN OUR UNDERSTANDING OF CUTANEOUS T-CELL LYMPHOMAS: NOVEL THERAPEUTIC APPROACHES** (Room B I)  
Chair: F.M. Foss (Boston, USA) and R. Dummer (Zürich, Switzerland)

04:30-6:30 p.m.  
parallel symposia  
MSD Oncology
**HDAC INHIBITION – A NOVEL APPROACH TO CANCER TREATMENT** (Room A)  
Chair: B. Cheson (Washington, USA)

Amgen (Europe) GmbH
**NEW DIMENSIONS IN GROWTH FACTOR SUPPORT: OPTIMIZING THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES** (Room B I)  
Chair: M. Pfreundschuh (Homburg, Germany)

Roche
**NEORECORMON® – JUST FOR ANAEMIA?** (Room B II)  
Chair: G. Gaidano (Novara, Italy)

07:30-9:30 p.m.  
parallel symposia  
Schering AG
**ZEVALIN®: TARGETING FOR CURE IN NHL** (Room A)  
Chair: A. Hagenbeek (Utrecht, The Netherlands)

Baxter Oncology GmbH
**NEW APPROACHES IN RELAPSING MALIGNANT LYMPHOMA** (Room B I)  
Chair: Ch. Gisselbrecht (Paris, France) and A.D. Zelenetz (New York, USA)

Lilly Oncology
**AGGRESSIVE LYMPHOMAS: LIFE AFTER (R) CHOP-BASED THERAPIES** (Room B II)  
Chair: R.I. Fisher (Rochester, USA)

WEDNESDAY, 8 JUNE 2005

07:00-9:00 p.m.  
parallel symposia  
Schering AG
**MABCAMPATH®: INCREASING SURVIVAL IN CLL** (Room A)  
Chair: A. Österborg (Stockholm, Sweden)

SuperGen/Eurogen
**NOVEL USES OF PENTOSTATIN FOR LYMPHOID MALIGNANCIES** (Room B I)  
Chair: F.M. Foss (Boston, USA)

Lipomed AG
**INNOVATIVE TREATMENT OPTIONS FOR INDOLENT LYMPHOMAS** (Room B II)  
Chair: D. Hoelzer (Frankfurt am Main, Germany) and E. Montserrat (Barcelona, Spain)
THURSDAY, 9 June 2005

07:00-09:00 p.m.  parallel symposia

Ortho Biotech – Millennium

NEW FRONTIERS IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA – THE POTENTIAL ROLE FOR PROTEASOME INHIBITION (Room A)
Chair: R.I. Fisher (Rochester, USA)

ADVANCES IN BIOLOGY AND THERAPY OF WALDENSTRÖM’S MACROGLOBULINEMIA (Room I)
A special symposium and dinner dedicated to the memory of Ben Rude, President of the International Waldenström’s Macroglobulinemia Foundation
Chair: S.P. Treon (Boston, USA)
Conference Schedule

WEDNESDAY, 8 June 2005

07:00 a.m.  POSTER SET UP I (Marquee Parco Ciani)

07:30 a.m.  POSTER SESSION I (Marquee Parco Ciani, authors present, posters posted the whole day)

09:00-09:45 a.m.  MEET THE PROFESSOR (part I) (repetition Thursday, 9 June, 07:30-08:15 a.m.)

THE ROLE OF PET IN LYMPHOMA STAGING (Room A)
T.F. Hany (Zürich, Switzerland)

RADIOIMMUNOTHERAPY (Room B I)
O.W. Press (Seattle, USA)

MARGINAL ZONE LYMPHOMAS (Room B II)
B. Coiffier (Pierre Bénite, France)

ROLE OF ZAP-70 IN ASSESSING PROGNOSIS IN CLL PATIENTS (Room C)
E. Montserrat (Barcelona, Spain)

CASTLEMAN’S DISEASE (Room E)
J.O. Armitage (Omaha, USA)

TREATMENT OF LYMPHOMA IN HIV POSITIVE PATIENTS (Room G)
R. Klasa (Vancouver, Canada)

10:00-10:45 a.m.  MEET THE PROFESSOR (part II)
(repetition Friday, 10 June, 07:30-08:15 a.m.)

TREATMENT OF VERY YOUNG PATIENTS WITH FOLLICULAR LYMPHOMA (Room A)
S.J. Hornung (Palo Alto, USA)

BIOLOGY OF MULTIPLE MYELOMA (Room B I)
K.C. Anderson (Boston, USA)

CNS LYMPHOMAS (Room B II)
A. Ferrari (Milan, Italy)

CUTANEOUS LYMPHOMA (Room C)
F.M. Foss (Boston, USA)

LYMPHOMAS OF THE HEAD AND NECK REGION (Room E)
K. Tobinai (Tokyo, Japan)

ACTIVE IMMUNOTHERAPY IN LYMPHOMAS (Room G)
R. Levy (Stanford, USA)

Endorsed by ASCO. This program has the American Society of Clinical Oncology’s approval for quality of educational content. ASCO endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment.
11:00-12:00 a.m. parallel sessions

POSTER DISCUSSIONS WITH DISCUSSION LEADERS (POSTER SESSION I)

AGGRESSIVE LYMPHOMAS IN ELDERLY PATIENTS (Room A)
Chairperson: J. Vose (posters # 221, 222, 223, 224, 225, 226, 227, 228, 229)

GASTRIC MALT LYMPHOMAS (Room B I)
Chairperson: M. Gospodarowicz (posters # 189, 190, 191, 192, 193, 194, 195)

BIOLOGY OF AGGRESSIVE LYMPHOMAS, INCLUDING GENE PROFILING (Room B II)
Chairperson: L. Staude (posters # 119, 120, 121, 122, 123, 124, 125, 126)

BIOLOGY OF HODGKIN’S DISEASE (Room C)
Chairperson: V. Diehl (posters # 155, 156, 157, 158, 159, 160, 161, 162, 163, 164)

12:00-01:00 p.m.

LUNCH AND OFFICIAL OPENING OF THE COMMERCIAL EXHIBITION
(Marquee Parco Ciani)

TIME       ABSTRACT                                           TITLE, AUTHORS

01:00 p.m.  OPENING OF THE CONFERENCE (Room A/B)
            WELCOME AND INTRODUCTORY REMARKS
            F. Cavalli (Bellinzona, Switzerland)

01:10 p.m.  AWARD OF THE SAN SALVATORE FOUNDATION (Room A/B)
            (combined with Kaplan Lecture)
            Introduction to the Foundation: G. Ghiringhelli, President of the Foundation
            Presentation of the Award: M. Baggiolini, Chairman Scientific Committee

01:20 p.m.  001 HENRY KAPLAN MEMORIAL LECTURE (Room A/B)
            LYMPHOMA RESEARCH: POINTING THE WAY IN MEDICAL ONCOLOGY
            G.P. Canellos (Boston, USA)

02:10-03:45 p.m.

SESSION 1 - VIROLOGY, EPIDEMIOLOGY (Room A/B)
Chairmen: J.-C. Piffaretti and J. Connors

02:10 002 NON-HODGKIN LYMPHOMA AROUND THE WORLD: DISTRIBUTION OF MAJOR TYPES
       DIFFERS BY GEOGRAPHIC REGION
       D.D. Weisenburger et al (Omaha, USA)

02:25 003 THE EFFECT OF REGULAR USE OF HAIR DYE ON LYMPHOID NEOPLASM IN EUROPE
       S. De Sanjose et al (Barcelona, Spain)

02:40 004 STATIN USE AND RISK OF LYMPHOMA. AN INTERNATIONAL CASE-CONTROL STUDY
       J. Fortuny et al (Barcelona, Spain)

02:55 005 EFFECT OF INDIVIDUAL HAART TREATMENT ON HODGKIN AND NON-HODGKIN LYM-
       PHOMA RISK AMONG HIV PATIENTS
       L. Dal Maso et al (Aviano, Italy)

03:10 006 HEPATITIS-C VIRUS-ASSOCIATED NON HODGKIN’S LYMPHOMAS
       P. Musto (S. Giovanni Rotondo, Italy)

03:25 007 EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS
       A.B. Rickinson (Birmingham, UK).
03:45-04:00 p.m.  INTERMISSION (Marquee Parco Ciani)

04:00-05:45 p.m.  SESSION 2 – MULTIPLE MYELOMA (Room A/B)

   Supported by unrestricted grant from Novartis Pharma Schweiz AG
   Chairmen: D. Höfler and S. P. Treon

04:00  008  BIOLOGY OF MULTIPLE MYELOMA: ONCOGENE ACTIVATION IN THE GERMINAL CENTER, AND A CRITICAL ROLE FOR CYCLIN D DYSREGULATION
   P.L. Bergsagel et al (Scottsdale, USA)

04:20  009  DNA AMPLIFICATION AND ELEVATED EXPRESSION OF CKS1B IS ASSOCIATED WITH REDUCED LEVELS OF P27KIP1 AND POOR SURVIVAL IN MULTIPLE MYELOMA
   J. Shaughnessy et al (Little Rock, USA)

04:35  010  NON-GENOTOXIC ACTIVATION OF THE P53-PATHWAY AS A THERAPEUTIC STRATEGY FOR MULTIPLE MYELOMA
   T. Stühmer et al (BERLIN, GERMANY)

04:50  011  TOTAL THERAPIES 1,2,3 FOR MULTIPLE MYELOMA: THE ARKANSAS EXPERIENCE WITH 1000 PATIENTS
   B. Barlogie et al (Little Rock, USA)

05:05  012  STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
   J.L. Harousseau (Nantes, France)

05:25  013  DEVELOPMENT OF NOVEL TARGETED THERAPIES FOR MYELOMA
   K.C. Anderson (Boston, USA)

05:45-06:30 p.m.  CONTROVERSY I - WHAT IS THE ROLE OF HIGH DOSE CHEMOTHERAPY FOR FOLLICULAR LYMPHOMA? (Room A/B)

   Chairman: W. Hiddemann

05:45  014  PATIENTS WITH FOLLICULAR LYMPHOMA SHOULD RECEIVE EARLY HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION - NOT
   S.J. Horning (Palo Alto, USA)

05:50  015  PATIENTS WITH FOLLICULAR LYMPHOMA SHOULD RECEIVE EARLY HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION - YES
   T.A. Lister (London, UK)

THURSDAY, 9 June 2005

07:30-08:15 a.m.  MEET THE PROFESSOR (repetition part I, same speakers, same rooms)

08:30-09:45 a.m.  parallel session

08:30  016  DISCRIMINATIVE VALUE OF THE IMMUNE RESPONSE AT DIAGNOSIS IN RAPIDLY TRANSFORMING FOLLICULAR LYMPHOMA
   D. De Jong et al (Amsterdam, The Netherlands)

08:45  017  THERAPEUTIC VACCINATION FOR LYMPHOMA
   R. Levy (Stanford, USA)
09:05  018  MOLECULAR MECHANISMS OF IMMUNE INHIBITION: NEW WAYS TO ENHANCE ACTIVE CANCER IMMUNOTHERAPY  
J.L. Schultz (Cologne, Germany)

09:25  019  REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED HODGKIN AND NON-HODGKIN LYMPHOMA LOWERS REGIMEN TOXICITY AND FACILITATES A GRAFT-VERSUS-LYMPHOMA EFFECT  
S. Mackinnon (London, UK)

08:30-09:40 a.m. parallel session

08:30  020  NEWLY IDENTIFIED G-SECRETASE INHIBITORS BLOCK NOTCH SIGNALING AND CONTROL MULTIPLE MYELOMA CELL PROLIFERATION  
O. Acikgoz et al (Berlin, Germany)

08:45  021  SOMATIC ACTIVATION OF MYC AND BCL6 INDUCES MULTIPLE MYELOMA AND DIFFUSE LYMPHOMA IN MICE  
D.F. Robbiani et al (New York, USA)

09:00  022  EVADING P53 ACTION DURING TUMOR DEVELOPMENT AND THERAPY  
S.W. Lowe (Cold Spring Harbor, USA)

09:20  023  THE PIM-2 ONCOGENE CONIFERS RAPAMYCIN RESISTANCE IN HEMATOPOIETIC CELLS  
C.B. Thompson et al (Philadelphia, USA)

09:40-10:00 a.m.

COFFEE BREAK WITH PASTRIES (Marquee Parco Ciani)

10:00-12:00 a.m.

SESSION 5 – BIOLOGY OF LYMPHOMAS II (Room A/B)  
Chairmen: F. Cotter and R. Dalla-Favera

10:00  024  PROGNOSTIC IMPACT OF GERMINAL CENTER ASSOCIATED PROTEINS AND CHROMOSOMAL BREAKPOINTS IN HIGH-RISK DLBCL  
G.W. Van Imhoff et al (Groningen, The Netherlands)

10:15  025  HIGH RESOLUTION GENOMIC PROFILING IN 151 HIGH GRADE NON-HODGKIN LYMPHOMAS USING ARRAY BASED COMPARATIVE GENOMIC HYBRIDIZATION  
S. Wessendorf et al (Ulm, Germany)

10:30  026  MOLECULAR DIAGNOSIS YIELDS MOLECULAR TARGETS IN LYMPHOMA  
L.M. Staudt (Bethesda, USA)

10:50  027  TRANSCRIPTIONAL PROFILES OF LARGE B-CELL LYMPHOMAS: MOLECULAR HETEROGENEITY AND RATIONAL THERAPEUTIC TARGETS  
M.A. Shipp (Boston, USA)

11:10  028  SUBTYPING OF MYC-BREAKPOINT-NEGATIVE DLBCL BY GENE EXPRESSION AND GENOMIC PROFILING  
M. Hummel (Berlin, Germany)

11:30  029  GENE EXPRESSION PROFILING OF PRIMARY HODGKIN/REED-STERNBERG CELLS  
E. Tiacci et al (Essen, Germany)

11:45  030  ABERRANT HYPERMUTATION OF PIM1, PAX5, RhoH/TTF AND cMYC IN NODULAR LYMPHOCYTE PREDOMINANCE HODGKIN’S DISEASE  
B. Falini et al (Perugia, Italy)
12:00-12:45 p.m.  
031  
HENRY RAPPAPORT MEMORIAL LECTURE (Room A/B)  
KEYNOTE LECTURE I  
ANTIGEN RECEPTOR AND BAFF RECEPTOR MEDIATED SURVIVAL OF NORMAL AND MALIGNANT B CELLS  
K. Rajewsky (Boston, USA)  

01:00-02:00 p.m.  
LUNCH, POSTERVIEWING & GUINNESS WORLD RECORD ATTEMPT  
(Marquee Parco Ciani)  

02:00-03:00 p.m.  
SESSION 6 – REVIEW LECTURES ON HODGKIN'S DISEASE (Room A/B)  
Chairmen: V. Diehl and G. Canellos  
02:00  
032  
LATE EFFECTS AFTER HODGKIN’S DISEASE: RECOMMENDATIONS FROM THE ROCKEFELLER FOUNDATION SPONSORED WORKSHOP ON REDUCING MORTALITY AND IMPROVING QUALITY OF LIFE IN LONG-TERM SURVIVORS OF HODGKIN’S DISEASE  
P. M. Mauch (Boston, USA)  
02:20  
033  
REFRACTORY OR RELAPSED HODGKIN LYMPHOMA  
J.M. Connors (Vancouver, Canada)  
02:40  
034  
ELDERLY PATIENTS WITH HODGKIN’S LYMPHOMA HAVE A POORER OUTCOME DUE TO TREATMENT-RELATED MORTALITY WHEN TREATED WITH MORE AGGRESSIVE APPROACHES: RESULTS OF THE STUDIES HD5-HD9 PERFORMED BY THE GERMAN HODGKIN STUDY GROUP  
A. Engert (Cologne, Germany)  

03:00-03:20 p.m.  
035  
SPECIAL LECTURE (Room A/B)  
TREATMENT AND OUTCOME IN ADOLESCENTS AND YOUNG ADULTS WITH INTERMEDIATE AND AGGRESSIVE NON-HODGKIN’S LYMPHOMA  
M.S. Cairo (New York, USA)  

03:20-03:30 p.m.  
INTERMISSION (Marquee Parco Ciani)  

03:30-05:45 p.m.  
036  
SESSION 7–CHRONIC LYMPHOCYTIC LEUKAEMIA (Room A/B)  
Chairmen: E. Montserrat and M. Björkholt  
03:30  
CLL SUBGROUPS CARRYING GENETIC HIGH-RISK FEATURES SUCH AS 11q-, 17p-, OR V3-21 USAGE SHOW A HIGH RATE OF DISCORDANT VH AND ZAP-70 STATUS  
A. Kröber et al (Ulm, Germany)  
03:45  
NEW PERSPECTIVES FROM THE NEW BIOLOGY OF CLL  
F. Caligaris-Cappio et al (Milan, Italy)  
04:05  
FIRST LINE THERAPY OF CLL, UPDATE 2005  
M.J. Hallek (Cologne, Germany)  
04:25  
CHEMIOIMMUNOTHERAPY OF CLL – A NEW GOLD STANDARD  
M.J. Keating et al (Houston, USA)  
04:45  
COMBINATION CHEMOTHERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND MITOXANTRONE INDUCES A HIGH RESPONSE RATE IN PREVIOUSLY UNTREATED CLL  
F. Bosch et al (Barcelona, Spain)
THURSDAY, 9 June 2005
(CONTINUATION SESSION 7-CHRONIC LYMPHOCYTIC LEUKAEMIA - Room A/B)

05:00 041 Efficacy of Subcutaneous Alemtuzumab (Campath-1H) in Genetic High-Risk, Flu Darabine-Refractory CLL: CLL2H Study of the German CLL Study Group
S. Stilgenbauer et al (Ulm, Germany)

05:15 042 Long-Term Disease Control of Poor-Risk Chronic Lymphocytic Leukemia by Allogeneic Stem Cell Transplantation with Nonmyeloablative Conditioning: Interim Results of a Prospective Study
P. Dreger et al (Heidelberg, Germany)

05:30 043 Outcome in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy With or Without Stem Cell Transplantation
A. Tsimberidou et al (Houston, USA)

05:45-06:30
CONTROVERSY II - IS R-CHOP THE STANDARD TREATMENT FOR DLCL?
(Room A/B)
Chairman: B. Coiffier

044 R-CHOP is Not the Standard Treatment for DLCL
M. Pfreundschuh (Homburg, Germany)

045 R-CHOP is the Standard Treatment for Advanced Stage, DLCL
R. Fisher (Rochester, USA)

FRIDAY, 10 June 2005

07:00 a.m. POSTER SET UP II (Marquee Parco Ciani)

07:30 a.m. POSTER SESSION II (Marquee Parco Ciani, authors present, posters posted the whole day)

07:30-08:15 a.m. MEET THE PROFESSOR (repetition part II, same speakers, same rooms)

08:30-10:00 a.m. SESSION 8 - 10 YEARS WHO CLASSIFICATION (Room A/B)
Chairpersons: E. Jaffe and J.O. Armitage

08:30 046 Will Gene Expression Profiling Replace the Pathologist?
R.D. Gascoyne (Vancouver, Canada)

08:50 047 WHO-EORTC Classification for Cutaneous Lymphomas
R. Willemze (Leiden, The Netherlands)

09:10 048 Typing of Mature Aggressive B-NHLS in the Context of the WHO Classification by a Comprehensive Interdisciplinary Approach Using Genome-Wide Molecular Techniques
H. Stein (Berlin, Germany)

09:30 049 Are Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma the Same Disease?
M.J. Keating et al (Houston, USA)

09:45 050 Lymphoplasmacytic Lymphoma, Waldenstrom’s Macroglobulinemia and Splenic Marginal Zone Lymphoma One Disease?
S.P. Treon (Boston, USA)
10:00-10:15 a.m.  COFFEE BREAK WITH PASTRIES (Marquee Parco Ciani)

10:15-11:50 a.m.  SESSION 9 – MANTLE CELL LYMPHOMA (Room A/B)
Chairmen: E. Campo and M.J. Keating

10:15  051  MANTLE CELL LYMPHOMA: TURNING CYCLIN D1 ON AND OFF
E. Epner et al (Portland, USA)

10:30  052  MANTLE CELL LYMPHOMA: WHAT'S NEW?
R.D. Gascoyne (Vancouver, Canada)

10:50  053  CURRENT STRATEGIES IN MANTLE CELL LYMPHOMA. CONVENTIONAL THERAPY
M. Dreyling (Munich, Germany)

11:10  054  HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANPLANTATION IN MANTLE CELLLYMPHOMA
W. Hiddemann (Munich, Germany)

11:30  055  NEW TREATMENTS FOR MANTLE CELL LYMPHOMA
W.H. Wilson (Bethesda, USA)

12:00-12:45 p.m.  JOHN ULTMANN MEMORIAL LECTURE
KEY NOTE LECTURE II (Room A/B)
Supported by a grant of ASCO

056  MOLECULAR PATHOGENESIS OF DIFFUSE LARGE B CELL LYMPHOMA
R. Dalla-Favera (New York, USA)

01:00-02:00 p.m.  LUNCH WITH POSTVIEWING (Marquee Parco Ciani)

02:00-03:45 p.m.  SESSION 10 – CLINICAL RESULTS IN LYMPHOMA I (Room A/B)
Chairpersons: S. Horning and M. Pfundschuh

02:00  057  OPTIMISATION OF BEACOPP FOR ADVANCED HODGKIN'S DISEASE: FURTHER RESULTS
FROM GERMAN HODGKIN STUDY GROUP TRIALS HD9 AND HD12
V. Diehl et al (Cologne, Germany)

02:15  058  A RANDOMISED CONTROLLED TRIAL OF ABVD VS TWO MULTI-DRUG REGIMENS FOR
ADVANCED HODGKIN LYMPHOMA – UPDATED RESULTS OF UKLG LY09
J.A. Radford et al (Manchester, UK)

02:30  059  RADIATION DOSE IN NON-HODGKIN'S LYMPHOMA: PRELIMINARY RESULTS OF UK
NCRN RANDOMISED TRIAL
P. Hoskin et al (Northwood, UK)

02:45  060  RITUXIMAB PLUS MITOXANTRONE, CHLORAMBUCIL, PREDNISOLON IS
SUPERIOR TO MCP ALONE IN ADVANCED INDOLENT AND FOLLICULAR
LYMPHOMA – RESULTS OF A PHASE III STUDY (OSHO#39)
M. Herold et al (Erfurt, Germany)

03:00  061  THE ROLE OF RITUXIMAB MAINTENANCE TREATMENT IN RELAPSED
FOLLICULAR NHL: AN INTERIM ANALYSIS OF THE EORTC RANDOMIZED
INTERGROUP TRIAL
A. Hagenbeek et al (Utrecht, The Netherlands)
03:15 062
HIGH DOSE THERAPY WITH AUTOLOGOUS HAEMATOPOIETIC PROGENITOR CELL SUPPORT AS CONSOLIDATION OF REMISSION IN PATIENTS WITH FOLLICULAR LYMPHOMA: LONG FOLLOW-UP OF ST. BARTHOLOMEW'S HOSPITAL AND DANA-FARBER CANCER INSTITUTE DATA
A. Rohatiner et al (London, UK)

03:30 063
FLIPI PREDICTS OUTCOME IN 65 PATIENTS WITH PREVIOUSLY UNTREATED INDOLENT NHL WHO RECEIVED BEXXAR® IN COMBINATION WITH CHEMOTHERAPY
J. Leonard (New York, USA)

03:45-06:30 p.m.  parallel session
SESSION 11 – CLINICAL RESULTS IN LYMPHOMA II (Room A)
Chairmen: T.A. Lister and A. Hagenbeck

03:45 064
SEQUENTIAL RADIOMUNOTHERAPY WITH TOSITUMOMAB/JODINE 131 TOSITUMOMAB FOLLOWED BY CHOP CHEMOTHERAPY FOR MANTLE CELL LYMPHOMA IS A SAFE AND HIGHLY EFFECTIVE REGIMEN
A. Zeleznitz et al (New York, USA)

04:00 065
YOTTRIUM-90 IBRITUMOMAB TIUXETAN (Zevalin) INDUCES HIGH RESPONSE RATES IN PREVIOUSLY TREATED PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
F. Morschhauser et al (Lille, France)

04:15 066
AUTOLOGOUS STEM CELL TRANSPLANTATION AS CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH LOW-INTERMEDIATE RISK DIFFUSE LARGE B-CELL LYMPHOMA AND OVEREXPRESSION OF BCL2 PROTEIN. RESULTS OF THE GELA TRIAL LN98-B2
P. Morel et al (Lens, France)

04:30 067
DOSE-ESCALATED CHOP PLUS ETOPOSIDE (MEGACHOP) FOLLOWED BY REPEATED TRANPLANTATION OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN YOUNGER PATIENTS WITH AGGRESSIVE NHL. A SERIES OF PHASE II STUDIES BY THE GERMAN HIGH-GRADE NHL STUDY GROUP
N. Schnitz et al (Hamburg, Germany)

04:45 068
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT DOES NOT IMPROVE OUTCOME IN THE FIRST-LINE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA – RESULTS OF A COMPREHENSIVE META-ANALYSIS
A. Engert et al (Cologne, Germany)

05:00 069
MYELOABLATIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT FOR NON-HODGKIN'S LYMPHOMA: 20-YEAR EXPERIENCE WITH FAMILY MEMBER AND VOLUNTEER UNRELATED DONORS
C. Toze et al (Vancouver, Canada)

05:15 070
TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS-RELATED LYMPHOMA WITH RISK-ADAPTED INTENSIVE CHEMOTHERAPY: FINAL ANALYSIS OF THE NHL-HIV 93 TRIAL BY THE GELA-GICAT INTERGROUP
N. Mounier et al (Paris, France)

05:30 071
HIGH-DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT AS 1.LINE TREATMENT IN PERIPHERAL T-CELL LYMPHOMAS
F. D'Amore et al (Aarhus, Denmark)

05:45 072
LONG-TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA. THE SPANISH LYMPHOMA COOPERATIVE GROUP EXPERIENCE
J. Rodriguez et al (Palma de Mallorca, Spain)
06:00  073  OUTCOME OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN A SINGLE INSTITUTION: THE BRITISH COLUMBIA EXPERIENCE
K.J. Savage et al (Vancouver, Canada)

06:15  074  CHLORAMBUCLIC VERSUS OBSERVATION AFTER ANTI-HELCOBACTER THERAPY IN LOW-GRADE GASTRIC LYMPHOMA: RESULTS OF THE INTERNATIONAL LY03 TRIAL
B. Hancock et al (Sheffield, UK)

04:00-06:30 p.m. parallel session

SESSION 12 – CLINICAL-PATHOLOGICAL CORRELATIONS (Room B)
Chairpersons: E. Jaffe and R. Gascoyne

04:00  075  NATIONWIDE INTEROBSERVER VARIATION IN THE DIAGNOSIS OF FOLLICULAR LYMPHOMA. A REPORT FROM THE PATHOLOGISTS OF G.I.S.L. (GRUPPO ITALIANO STUDI LINFOMI)
C. Tripodo et al (Palermo, Italy)

04:15  076  INTRA-FOLLICULAR PROLIFERATION RATE IS SUPERIOR TO HISTOLOGICAL GRADING IN PREDICTING OUTCOME IN FOLLICULAR LYMPHOMA
A. Koster et al (Nijmegen, The Netherlands)

04:30  077  BURKITT-LIKE FEATURES IS ASSOCIATED WITH A POOR PROGNOSIS AND C-MYC AMPLIFICATION IN NHL
D. Damotte et al (Paris, France)

04:45  078  MEMBRANE EXPRESSION OF PKC-BETA 2 PROTEIN IDENTIFIES A SUBGROUP OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA WITH POOR SURVIVAL
J. Briones et al (Barcelona, Spain)

05:00  079  STUDY OF THE TREATMENT AND BIOLOGY OF LYMPHOMATOID GRANULOMATOSIS: A RARE EBV LYMPHOPROLIFERATIVE DISORDER
K. Dunleavy et al (Bethesda, USA)

05:15  080  HETEROGENEITY OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: NATIONAL SURVEY OF KOREAN CANCER STUDY GROUP
S. Lee et al (Seoul, Korea)

05:30  081  CIRCULATING CD10 POSITIVE T-CELLS IN THE DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
L. Basaggio et al (Pierre Bénite, France)

05:45  082  BLASTIC NK CELL LYMPHOMA OF THE WHO CLASSIFICATION: A NOVEL DISEASE DERIVED FROM PLASMACYTOID DENDRITIC CELLS
H. Ebbingardt and H. Stein (Berlin, Germany)

06:00  083  GASTROINTESTINAL INVOLVEMENT IN MANTLE CELL LYMPHOMA. A CLINICOPATHOLOGIC STUDY
A. Salar et al (Barcelona, Spain)

06:15  084  ATYPICAL CYTOGENETIC PRESENTATION OF T(11;14) OCCURRED IN MORE THAN 17% OF MANTLE CELL LYMPHOMA PATIENTS
E. Callet-Bauchu et al (Pierre Bénite, France)

04:00-06:30 p.m. parallel session

SESSION 13 – PEDIATRIC LYMPHOMAS (Room C)
Chairman: A. Reiter

04:00  085  SPECIAL LECTURE
THE 15-20 YEAR OLD PATIENTS WITH NHL TREATED IN FRANCE: DATA OF CHILDHOOD AND ADULT DATABASES
C. Patte et al (Villejuif, France)
04:20  086  THE IMPACT OF AGE AND SEX ON INCIDENCE, BIOLOGY AND TREATMENT OUTCOME OF NON-HODGKIN LYMPHOMA IN CHILDHOOD AND ADOLESCENCE B. Burkhardt et al (Giessen, Germany)

04:35  087  DIFFUSE LARGE B-CELL LYMPHOMAS IN PEDIATRIC PATIENTS DEMONSTRATE A MARKED PREDOMINANCE OF GERMINAL CENTER CELL PHENOTYPE R. Miles et al (Salt Lake City, USA)

04:50  088  PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN CHILDREN/ADOLESCENTS. DATA OF EUROPEAN AND AMERICAN GROUPS C. Patte et al (Villejuif, France)

05:05  089  A NOVEL APPROACH FOR STAGING AND MINIMAL RESIDUAL DISEASE DETECTION IN T-CELL LYMPHOBLASTIC LYMPHOMA – A CHILDREN’S ONCOLOGY GROUP STUDY D. Campana et al (Memphis, USA)

05:20  090  SALVAGE STRATEGY FOR ANAPLASTIC LARGE CELL LYMPHOMA IN CHILDREN: PROGNOSTIC IMPACT OF TIME OF RELAPSE AND CD3 REACTIVITY W. Woessmann et al (Giessen, Germany)

05:35  091  DELETION OF CRANIAL IRRADIATION AND ADDITION OF SYSTEMIC HIGH DOSE METHOTREXATE AND INTRATHECAL CHEMOTHERAPY RESULTS IN 70% 4-YR. EFS IN CHILDREN AND ADOLESCENTS WITH CNS POSITIVE B-NHL: RESULTS OF INTERNATIONAL FAB/LMB 96 STUDY M.S. Cairo et al (New York, USA)

05:50  092  CYTOGENETIC ANALYSIS OF 237 PEDIATRIC MATURE B-CELL NON HODGKIN LYMPHOMA CASES (FAB/LMB96) EXHIBITS SEVERAL PATTERNS OF CHROMOSOMAL ALTERATIONS AND NEW PROGNOSTIC FACTORS H.A. Poirel et al (Paris, France)

06:05  093  PROGNOSTIC FACTORS IN CHILDHOOD/ADOLESCENT B-CELL LYMPHOMA: RESULTS OF THE INTERNATIONAL FAB/LMB 96 STUDY C. Patte et al (Villejuif, France)

06:20  Discussion

06:30-07:30 p.m. parallel sessions

POSTER DISCUSSIONS WITH DISCUSSION LEADERS (POSTER SESSION II)
This poster discussion includes a special group discussing lymphoma transformation with an introduction of:

06:30  094  INCIDENCE, PREDICTIVE FACTORS AND OUTCOME OF TRANSFORMED LYMPHOMA: A POPULATION-BASED STUDY FROM BRITISH COLUMBIA (Room A) A. Al-Tourah et al (Vancouver, Canada)

LYMPHOMA TRANSFORMATION (Room A)
Chairman: J. Connors (posters # 230, 231, 232, 233, 234, 235, 236, 237)

LONG TERM TREATMENT TOXICITY (Room B I)
Chairman: J. Redford (posters # 271, 272, 273, 274, 275, 276, 277, 278, 279)

ROLE OF PET (Room B II)
Chairman: G. Canellis (posters # 280, 281, 282, 283, 284, 285, 286, 287, 288, 289)

CNS AND ORBITAL LYMPHOMAS (Room C)
Chairman: P. Mauch (posters # 296, 297, 298, 299, 300, 301, 302, 303)

08:00 p.m.
09:00-01:00 a.m.

LUGANO CIRCUS SCHOOL OF LYDIA GOLOVKOVA (Room A)
FAREWELL PARTY (Marquee Parco Ciani)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td><strong>SESSION 14 – NEW AGENTS</strong> (Room A)</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>FINAL RESULTS OF A PHASE II TRIAL OF SINGLE-AGENT TEMSIROLIMUS (CCI-779) FOR</td>
<td>T. Witzig et al (Rochester, USA)</td>
</tr>
<tr>
<td></td>
<td>RELAPSED MANTLE CELL LYMPHOMA</td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td>FLAVOPIRIDOL GIVEN AS A 30-MIN INTRAVENOUS BOLUS FOLLOWED BY 4-HR CONTINUOUS</td>
<td>T. Lin et al (Columbus, USA)</td>
</tr>
<tr>
<td></td>
<td>IV INFUSION RESULTS IN CLINICAL ACTIVITY AND TUMOR LYSIS IN REFRACTORY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHRONIC LYMPHOCYTIC LEUKEMIA</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>BORTEZOMIB (VELCADE®) IN PATIENTS WITH RELAPSED/REFRACTORY</td>
<td>S. Strauss et al (London, UK)</td>
</tr>
<tr>
<td></td>
<td>LYMPHOMA: POTENTIAL CORRELATION OF TNFα RESPONSE AND IN VITRO SENSITIVITY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WITH CLINICAL ACTIVITY</td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td>PHASE II STUDY OF BORTEZOMIB IN RELAPSED/REFRACTORY WALDENSTROM’S</td>
<td>Z. Hunter et al (Boston, USA)</td>
</tr>
<tr>
<td></td>
<td>MACROGLOBULINEMIA: INTERIM RESULTS OF WMCTG 03-248</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>TARGETING THE PROTEASOME PATHWAY WITH BORTEZOMIB IN PATIENTS WITH</td>
<td>O. O’Connor et al (New York, USA)</td>
</tr>
<tr>
<td></td>
<td>MANTLE CELL AND POLYCLINIC LYMPHOMA PRODUCES PROLONGED PROGRESSION FREE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SURVIVAL AMONG RESPONDING PATIENTS: RESULTS OF A MULTICENTER PHASE II</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EXPERIENCE</td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td>GEMCITABINE AS FRONT-LINE TREATMENT FOR CUTANEOUS T-CELL LYMPHOMAS: PHASE II</td>
<td>L. Zinzani et al (Bologna, Italy)</td>
</tr>
<tr>
<td></td>
<td>STUDY ON 32 PATIENTS</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>NEW DRUGS FOR LYMPHOMAS</td>
<td>B.D. Cheson (Washington, USA)</td>
</tr>
<tr>
<td>10:20</td>
<td>REPORT ON WORKSHOP ON T-CELL LYMPHOMAS</td>
<td>F.M. Foss (Boston, USA)</td>
</tr>
<tr>
<td>10:40</td>
<td>FOLLOW-UP OF THE LUGANO WORKSHOPS (1990-2002)</td>
<td>F. Cavalli (Bellinzona, Switzerland)</td>
</tr>
<tr>
<td>10:50</td>
<td>CLOSING REMARKS</td>
<td>J.O. Armitage (Omaha, USA)</td>
</tr>
<tr>
<td>11:00</td>
<td>CLOSE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45-10:30 a.m.</td>
<td><strong>SESSION 15 – NEW TREATMENT MODALITIES</strong> (Room B)</td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td>A PHASE II TRIAL OF OBLIMERSEN SODIUM (G3139) PLUS RITUXIMAB FOR TREATMENT</td>
<td>B. Pro et al (Houston, USA)</td>
</tr>
<tr>
<td></td>
<td>OF PATIENTS WITH RECURRING B-CELL NON-HODGKIN’S LYMPHOMA</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>RITUXIMAB PLUS GM-CSF (LEUKINE®) FOR INDOLENT LYMPHOMA</td>
<td>P. McLaughlin et al (Houston, USA)</td>
</tr>
<tr>
<td>09:15</td>
<td>PHASE I STUDY OF INTRAVENTRICULAR ADMINISTRATION OF RITUXIMAB IN</td>
<td>J. Rubenstein et al (San Francisco, USA)</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH RECURRENT INTRAOCULAR AND CNS LYMPHOMA</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>CLINICAL UPDATE ON FRACTIONATED RADIOIMMUNOTHERAPY IN PATIENTS WITH NHL</td>
<td>J. Chatal et al (Nantes, France)</td>
</tr>
<tr>
<td></td>
<td>USING HUMANIZED 90Y LABELED ANTI-CD22 EPRATUZUMAB</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td>107</td>
<td>RAPID INFUSION RITUXIMAB CAN BE SAFELY ADMINISTERED AND HAS A POSITIVE IMPACT ON RESOURCE UTILIZATION L. Sehn et al (Vancouver, Canada)</td>
</tr>
<tr>
<td>10:00</td>
<td>108</td>
<td>DOSE-ADJUSTED EPOCH-RITUXIMAB: A NOVEL PHARMACODYNAMIC REGIMEN WITH HIGH EFFICACY IN ALL CLINICAL RISK GROUPS, AND GCB AND ABC SUBTYPES OF UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA W. Wilson et al (Bethesda, USA)</td>
</tr>
<tr>
<td>10:15</td>
<td>109</td>
<td>THE LUNENBURG LYMPHOMA BIOMARKER CONSORTIUM: DEVELOPING BIOMARKERS FOR CLINICAL USAGE G. Salles et al (Pierre Bénite, France)</td>
</tr>
<tr>
<td>10:50</td>
<td></td>
<td>CLOSING REMARKS (Room A) J.O. Armitage (Omaha, USA)</td>
</tr>
<tr>
<td>08:15-10:30 a.m.</td>
<td>SESSION 16 – NEW IMMUNOLOGICAL PRINCIPLES (Room C) parallel session Chairmen: J. Schultzze and R. Levy</td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td>110</td>
<td>TRIGGERING OF TRAIL-R1 AND TRAIL-R2 DEATH RECEPTORS BY THEIR SELECTIVE FULLY HUMAN AGONISTIC ANTIBODIES INDUCES APOPTOSIS IN PRIMARY AND CULTURED LYMPHOMA CELLS G. Georgakis et al (Houston, USA)</td>
</tr>
<tr>
<td>08:30</td>
<td>111</td>
<td>GCS-100 A NOVEL GALECTIN-3 ANTAGONIST AND CASPASE9 ACTIVATING THERAPY FOR INDOLENT B-CELL MALIGNANCIES F. Cotter et al (London, UK)</td>
</tr>
<tr>
<td>08:45</td>
<td>112</td>
<td>THE USE OF AUTOLOGOUS LMP2-SPECIFIC CYTOTOXIC T LYMPHOCYTES FOR THE TREATMENT OF RELAPSED EBV + VE HODGKIN DISEASE AND NON-HODGKIN LYMPHOMA C. Boillard et al (Houston, USA)</td>
</tr>
<tr>
<td>09:00</td>
<td>113</td>
<td>HUMAX-CD4 A FULLY HUMAN ANTI-CD4 MONOCLONAL ANTI-BODY: PHASE II TRIAL IN CUTANEOUS T-CELL LYMPHOMA M. Duvic et al (Houston, USA)</td>
</tr>
<tr>
<td>09:15</td>
<td>114</td>
<td>A NOVEL FULLY HUMAN ANTI-CD20 MONOCLONAL ANTIBODY: FIRST clinical results from an ongoing phase I/II trial in patients with follicular non-hodgkin's lymphoma A. Hagenbeek et al (Utrecht, The Netherlands)</td>
</tr>
<tr>
<td>09:30</td>
<td>115</td>
<td>RESULTS FROM A PHASE I/II STUDY OF GALIXIMAB (ANTI-CD80) IN COMBINATION WITH RITUXIMAB (ANTI-CD20) FOR RELAPSED OR REFRACTORY, FOLLICULAR NHL J. Leonard et al (New York, USA)</td>
</tr>
<tr>
<td>09:45</td>
<td>116</td>
<td>PHASE I/II STUDY OF THE ANTI-CD30 ANTIBODY MDX-069 IN PATIENTS WITH REFRACTORY/RELAPSED CD30 POSITIVE LYMPHOMA P. Borchmann et al (Cologne, Germany)</td>
</tr>
<tr>
<td>10:00</td>
<td>117</td>
<td>ROLE OF MICROENVIRONMENT IN INHIBITION OF APOPTOSIS IN B-CELL CELLS: REGULATION BY PI3-K INHIBITORS AND siRNA M. Shehata et al (Vienna, Austria)</td>
</tr>
<tr>
<td>10:15</td>
<td>118</td>
<td>CLINICAL REMISSIONS IN PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR LYMPHOMA AFTER INTRADERMAL IMMUNIZATION WITH A RECOMBINANT IDIOTYPE VACCINE H. Veelken et al (Freiburg, Germany)</td>
</tr>
<tr>
<td>10:50</td>
<td></td>
<td>CLOSING REMARKS (Room A) J.O. Armitage (Omaha, USA)</td>
</tr>
</tbody>
</table>